U.S. License Holder:
Sandoz
Date of License:
November-04-2019
Last Update:
June-23-2025
FDA-Approved Indications
ZIEXTENZO (pegfilgrastim-bmez) is a leukocyte growth factor indicated to
Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia;
Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In Canada
Ziextenzo® (Sandoz) (April-2020)
Biosimilars Approved In The E.U.
Ziextenzo® (Sandoz) (November-2018)
U.S. Patent Litigations
